Core Insights - Lung nodules have become common in health check reports, with most being benign, but regular follow-ups are essential based on nodule characteristics [1][2] Group 1: Lung Nodule Management - 95% of lung nodules are benign, with only 5% having the potential for malignancy [2] - Recommendations for follow-up include: - Ground-glass nodules under 5mm should be reviewed every six months - Nodules between 5mm and 1cm should be followed up every three months - Mixed nodules under 8mm should follow a 3-6-12 month follow-up schedule, while those over 8mm may require intervention [2] - Solid nodules require comprehensive evaluation based on size and edge characteristics, with anti-inflammatory treatment potentially ruling out malignancy if nodules shrink [2] Group 2: Lung Cancer Risk Factors - Lung cancer has the highest incidence and mortality rates among all malignancies in China, with primary risk factors including smoking, occupational exposure, and chronic lung diseases [3] - Smoking significantly increases cancer risk, with smokers having a 4-10 times higher mortality rate compared to non-smokers [3] - Passive smoking and occupational exposures, such as asbestos and air pollution, also contribute to increased risk [3] Group 3: Lung Cancer Treatment Approaches - The pathological classification of lung cancer determines treatment strategies, with small cell lung cancer (15% of cases) being highly malignant but treatable with combined therapies extending median survival from 18 months to 55.9 months [4] - Immunotherapy combined with chemotherapy has become a first-line treatment for extensive small cell lung cancer, achieving an objective response rate of 60%-70% [4] - Despite advancements in targeted and immunotherapy, chemotherapy remains a crucial treatment method, with modern regimens improving management of side effects [4]